SS 30 - Optimizing Therapy, Toxicity, and Supportive Care in Head & Neck Cancers

Presentations

• 12:30pm - 12:39pm ET

  The HYPCON Trial 2: A Phase II Randomized Study Evaluating Hypofractionated vs. Conventional Adjuvant Concurrent Chemoradiation in Head and Neck Malignancies

  Speaker: Aarcha Ramadas, MBBS - AIIMS New Delhi, New Delhi
• 12:30pm - 01:45pm ET

  Optimizing Therapy, Toxicity, and Supportive Care in Head & Neck Cancers

  Speaker: Philip Schaner, MD, PhD - Dartmouth-Hitchcock Medical Center, Lebanon
• 12:30pm - 01:45pm ET

  Optimizing Therapy, Toxicity, and Supportive Care in Head & Neck Cancers

  Speaker: Yvonne Mowery, MD, PhD, BS - University of Pittsburgh Medical Center, Pittsburgh
• 12:39pm - 12:48pm ET

  BEYOND PAIN SCORES: PHOTOBIOMODULATION REDUCES ANALGESIC BURDEN AND IMPROVES TREATMENT TOLERANCE DURING CHEMORADIOTHERAPY FOR ORAL CAVITY CANCER

  Speaker: Siddhartha Nanda, MD - All India Institute of Medical Sciences, Raipur
• 12:48pm - 12:57pm ET

  Comparison of Xerostomia in Head and Neck Cancer Patients Undergoing Radiation with and without Parotid Duct Sparing via MRI Sialography: A Randomised Control Study

  Speaker: Pritanjali Singh, MBBS, DNB - All India Institute of Medical Sciences Patna, Patna
• 12:57pm - 01:06pm ET

  First Report from the Headlight Trials: Postoperative Hypofractionated Proton Therapy for Head and Neck Cancers Unrelated to HPV

  Speaker: Scott Lester, MD - Mayo Clinic Rochester, Rochester
• 01:06pm - 01:15pm ET

  Baseline Carotid Artery Calcium Score Is Associated with High-Risk Carotid Ultrasound Findings In Head and Neck Cancer Survivors after Radiation Therapy: Secondary Analysis of a Prospective Study

  Speaker: Jacob Johnson, BS - Wake Forest University School of Medicine, Winston-Salem
• 01:15pm - 01:24pm ET

  Discussant

  Speaker: Kenneth Shung Hu, MD, FASTRO - New York University, New York